In 2023, the ten largest foreign pharmaceutical companies significantly reduced payments to Russian doctors, reducing expenses for conferences, travel and consultations with doctors by 652.6 million rubles. – 17% less than a year ago. The leader in payment volume, Germany’s Bayer, reduced payments by 31%, from 336.6 million rubles. to 230.6 million rubles. writes about this RBC according to their own calculations.
GlaxoSmithKline, Takeda and Novo Nordisk have completely stopped paying Russian doctors, significantly reducing the amount of funding provided to doctors from the Russian Federation. At the same time, the companies did not completely abandon the practice: at least four doctors cooperating with Bayer received more than 1 million rubles. Each.
“The reduction in payments was the result of a change in approach to the business. We focused solely on activities that provide the greatest value in improving physicians’ knowledge of the correct use of our products, including digital solutions,” Bayer said.
Nikolai Bespalov, Director of RNC Drug Development, attributed this decrease to the suspension of marketing programs in Russia by many foreign companies after the start of SVO. Falling sales forced them to respond and expand their work with doctors, but in 2023 they switched to other promotional channels.
Before this the Russians clarified Possible infection with a “brain-eating” amoeba from Israel.
Earlier in the Kremlin taken into consideration The birth rate in the Russian Federation is disastrous.